• Je něco špatně v tomto záznamu ?

Delivery of doxorubicin using protein nanocarriers

Simona Dostálová, Dita Műnzová, Markéta Vaculovičová, René Kizek

Jazyk angličtina Země Česko

Typ dokumentu práce podpořená grantem, srovnávací studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc15013345

Anthracycline antibiotic drugs are widely used in treatment of many patients with cancer. First anthracycline drug, daunomycin (or daunorubicin) was found in a number of different wild type strains of Streptomyces. However, in cancer treatment the most commonly used anthracycline drug is doxorubicin (DOX) or one of its 2000 known analogs1. DOX is used in treatment of many different types of cancer such as neuroblastomas, leukaemia, lymphomas or breast, testicle, ovarian, lung, bladder, thyroid gland or head and neck carcinomas. Although it is so widely used, many side effects have been observed in patients such as sores in mouth and on lips, darkening of palms and nails, unusual bleeding and bruising, nausea and vomiting, and life-threatening cardiotoxicity 2. To eliminate the negative side effects of cancer treatment, researchers are trying to find either new analogs of DOX which are non-toxic for healthy cells or new way to deliver DOX directly into the cancer cells. For targeted delivery, it is possible to administer the drug directly into solid tumor. However, non-solid tumors or tumors with unknown location in patient’s body require encapsulation of DOX in suitable nanocarrier. Liposomal form of DOX is already being sold under the trade name Myocet 3. For enhanced biocompatibility, the liposomes were modified with polyethylene glycol under the trade name Doxil 4. Protein based natural nanocarriers in comparison with artificial nanocarriers seem to be more suitable for delivery of the drugs in patient’s body because of their lower immune response. The protein nanocarriers are usually self-assembled and can either be protein cages, viral capsids or virus-like particles 5. In this work, we compared two types of protein nanocarriers – phage λ and apoferritin, by their ability to encapsulate anthracycline drug doxorubicine. The encapsulation was verified by fluorescence of doxorubicin after the removal of free, non-encapsulated doxorubicin by dialysis.

Bibliografie atd.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc15013345
003      
CZ-PrNML
005      
20150610135807.0
007      
ta
008      
150416s2014 xr d f 000 0|eng||
009      
AR
040    __
$a ABA008 $d ABA008 $e AACR2 $b cze
041    0_
$a eng
044    __
$a xr
100    1_
$a Dostálová, Simona $7 _AN082240 $u Department of Chemistry and Biochemistry, Mendel University in Brno; Central European Institute of Technology, Brno University of Technology
245    10
$a Delivery of doxorubicin using protein nanocarriers / $c Simona Dostálová, Dita Műnzová, Markéta Vaculovičová, René Kizek
504    __
$a Literatura
520    3_
$a Anthracycline antibiotic drugs are widely used in treatment of many patients with cancer. First anthracycline drug, daunomycin (or daunorubicin) was found in a number of different wild type strains of Streptomyces. However, in cancer treatment the most commonly used anthracycline drug is doxorubicin (DOX) or one of its 2000 known analogs1. DOX is used in treatment of many different types of cancer such as neuroblastomas, leukaemia, lymphomas or breast, testicle, ovarian, lung, bladder, thyroid gland or head and neck carcinomas. Although it is so widely used, many side effects have been observed in patients such as sores in mouth and on lips, darkening of palms and nails, unusual bleeding and bruising, nausea and vomiting, and life-threatening cardiotoxicity 2. To eliminate the negative side effects of cancer treatment, researchers are trying to find either new analogs of DOX which are non-toxic for healthy cells or new way to deliver DOX directly into the cancer cells. For targeted delivery, it is possible to administer the drug directly into solid tumor. However, non-solid tumors or tumors with unknown location in patient’s body require encapsulation of DOX in suitable nanocarrier. Liposomal form of DOX is already being sold under the trade name Myocet 3. For enhanced biocompatibility, the liposomes were modified with polyethylene glycol under the trade name Doxil 4. Protein based natural nanocarriers in comparison with artificial nanocarriers seem to be more suitable for delivery of the drugs in patient’s body because of their lower immune response. The protein nanocarriers are usually self-assembled and can either be protein cages, viral capsids or virus-like particles 5. In this work, we compared two types of protein nanocarriers – phage λ and apoferritin, by their ability to encapsulate anthracycline drug doxorubicine. The encapsulation was verified by fluorescence of doxorubicin after the removal of free, non-encapsulated doxorubicin by dialysis.
650    12
$a systémy cílené aplikace léků $7 D016503
650    12
$a doxorubicin $7 D004317
650    _2
$a apoferritiny $7 D001052
650    _2
$a bakteriofág lambda $7 D010582
650    _2
$a nanostruktury $7 D049329
650    _2
$a nanomedicína $7 D050997
650    _2
$a fluorescence $7 D005453
653    00
$a enkapsulace léčiv
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a srovnávací studie $7 D003160
700    1_
$a Münzová, Dita $7 _AN082246 $u Department of Chemistry and Biochemistry, Mendel University in Brno
700    1_
$a Vaculovičová, Markéta $7 _AN082228 $u Department of Chemistry and Biochemistry, Mendel University in Brno;Central European Institute of Technology, Brno University of Technology
700    1_
$a Kizek, René, $d 1972- $7 jn20001005291 $u Department of Chemistry and Biochemistry, Mendel University in Brno; Central European Institute of Technology, Brno University of Technology
773    0_
$t Journal of Metallomics and Nanotechnologies $x 2336-3940 $g Roč. 1, č. 4 (2014), s. 34-38 $w MED00185603
856    41
$u http://web2.mendelu.cz/af_239_nanotech/J_Met_Nano/0414/pdf/JMN4-00-07.pdf $y plný text volně přístupný
910    __
$a ABA008 $b B 2733 $c 398 $y 4 $z 0
990    __
$a 20150415135905 $b ABA008
991    __
$a 20150610140154 $b ABA008
999    __
$a ok $b bmc $g 1070972 $s 896217
BAS    __
$a 3
BMC    __
$a 2014 $b 1 $c 4 $d 34-38 $i 2336-3940 $m Journal of Metallomics and Nanotechnologies $x MED00185603
LZP    __
$c NLK188 $d 20150610 $a NLK 2015-15/pk

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...